Spironolactone-induced gynecomastia

Cuculi, Florim; Suter, Alex; Erné, Paul

doi:10.1503/cmaj.061286

Cited by 7 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 4 5 6 ] The antiandrogen action of spironolactone responsible for the development of gynecomastia depends on the dose and duration of treatment and is usually bilateral. [ 6 7 8 ] A study conducted by Rose et al . has reported that 6 out of 16 patients with hypertension treated with spironolactone developed gynecomastia.…”

Section: Discussionmentioning

confidence: 99%

Spironolactone-induced unilateral gynecomastia

Veeregowda

Krishnamurthy

Krishnaswamy

et al. 2018

Int J App Basic Med Res

View full text Add to dashboard Cite

Gynecomastia is benign enlargement of male breast, drug-induced gynecomastia accounts for about 25%. We are reporting a case of spironolactone-induced unilateral gynecomastia. A 52-year-old male patient receiving multiple antihypertensives including hydrochlorothiazide presented with muscle weakness and easy fatigability. Investigations revealed hypokalemia; he was advised to stop hydrochlorothiazide and consume potassium-rich diet; since he did not respond to this, spironolactone was added. The patient improved symptomatically but developed painful swelling of the right breast after 12 months of treatment which was suspected to be spironolactone-induced gynecomastia. Within a month of stopping the drug, pain in the right breast subsided followed by decrease in size of swelling. Literature search indicates bilateral gynecomastia by spironolactone, but when clinician encounters unilateral presentation, they should consider the possibility of drug-induced etiology. Patients should be educated about this while prescribing, and eplerenone can be a safe alternative.

show abstract

Section: Discussionmentioning

confidence: 99%

Spironolactone-induced unilateral gynecomastia

Veeregowda

Krishnamurthy

Krishnaswamy

et al. 2018

Int J App Basic Med Res

View full text Add to dashboard Cite

show abstract

“…Eplerenone is a selective aldosterone receptor antagonist that does not bind to progesterone or androgen receptors and is not associated with breast pain, gynecomastia, or impotence . Additional studies have confirmed that eplerenone reverses spironolactone‐induced gynecomastia and related symptoms in patients with cirrhosis and hyperaldosteronism …”

Section: Antihypertensivesmentioning

confidence: 99%

Drug‐Induced Gynecomastia

2012

View full text Add to dashboard Cite

Drugs account for about 20% of gynecomastia cases in men. As a number of factors can alter the estrogen:androgen ratio, several pathophysiologic mechanisms are associated with drugs causing this disorder. Antiandrogens, protease inhibitors, and nucleoside reverse transcriptase inhibitors are the most common drug causes of gynecomastia, whereas first-generation antipsychotics, spironolactone, verapamil, and cimetidine are less common causes. Other drugs have been reported rarely as causes. Treatment may involve switching to an alternative agent or may require surgery or irradiation if the causative agent cannot be discontinued. We reviewed the literature on drug-induced gynecomastia and provided another perspective by reviewing data from the United States Food and Drug Administration's Adverse Event Reporting System. Epidemiologic studies are needed to provide a more accurate description of the frequency of drug-induced gynecomastia.

show abstract

“…Common problems with it's use include gynaecomastia, and electrolyte disturbances such as hyperkalaemia and deteriorating renal function. The later two are more common in patients in whom renal function is already compromised, and in patients already on ACE inhibitors or ARBs [80][81][82][83][84].…”

Section: Pharmacological Treatments For Htnmentioning

confidence: 99%

Hypertension: Pathophysiology and Treatment

Delacroix¹,

Chokka²

2014

J Neurol Neurophysiol

View full text Add to dashboard Cite

Hypertension is a significant risk factor for heart disease, stroke and other cardiovascular diseases and an estimated 970 million people worldwide suffer from the disease resulting in significant morbidity, mortality and financial burden globally. Despite significant advances in pharmaceutical treatment only 53% achieve targeted blood pressure goals largely due to poor patient compliance compelling a structured and flexible yet, individually tailored approach for treatment of HTN.1, 2This review addresses the pathophysiology, diagnosis and current management for the disease.

show abstract

Spironolactone-induced gynecomastia

Cited by 7 publications

References 2 publications

Spironolactone-induced unilateral gynecomastia

Spironolactone-induced unilateral gynecomastia

Drug‐Induced Gynecomastia

Hypertension: Pathophysiology and Treatment

Contact Info

Product

Resources

About